Antineoplastic Agents: Cytotoxic Agents: Alkylating Agents
IKEMO1 “Kemoplat injection” 0.5 mg/ml; 20 ml/vial
適應症：抗惡性腫瘍劑。
Usual dose:
Bladder cancer: single agent 50-70 mg/m2 IV per cycle q3-4w.
Ovarian cancer, metastatic (single): IV, 100 mg/m2/cycle q4w as a single agent.
Ovarian cancer, metastatic(combination): IV, 75-100 mg/m2/cycle q4w on Day-1 in combination with cyclophosphamide; Intraperitoneal, 90-200 mg/m2 q3w.
Testicular cancer, metastatic: 20 mg/m2 IV every day for 5 days per cycle with other approved agents.
Dose adjustment:
Renal impairment: repeat courses should not be given until serum creatinine is below 1.5 mg/100 ml and/or BUN < 25 mg/100 ml.
Hematologic: repeat courses should not be given until platelets≧100,000/mm3, white blood cell count≧4,000/mm3.
Adverse effect:
Common: electrolyte disturbances.
Serious: myelosuppression, nausea, vomiting, nephrotoxicity, ototoxicity, peripheral neuropathy.